Literature DB >> 22016505

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.

G Michael Felker1, Mona Fiuzat, Linda K Shaw, Robert Clare, David J Whellan, Luca Bettari, Shailesh C Shirolkar, Mark Donahue, Dalane W Kitzman, Faiez Zannad, Ileana L Piña, Christopher M O'Connor.   

Abstract

BACKGROUND: Galectin-3 is a soluble ß-galactoside-binding lectin released by activated cardiac macrophages. Elevated levels of galectin-3 have been found to be associated with adverse outcomes in patients with heart failure. We evaluated the association between galectin-3 and long-term clinical outcomes in ambulatory heart failure patients enrolled in the HF-ACTION study. METHODS AND
RESULTS: HF-ACTION was a randomized, controlled trial of exercise training in patients with chronic heart failure caused by left ventricular systolic dysfunction. Galectin-3 was assessed at baseline in a cohort of 895 HF-ACTION subjects with stored plasma samples available. The association between galectin-3 and clinical outcomes was assessed using a series of Cox proportional hazards models. Higher galectin-3 levels were associated with other measures of heart failure severity, including higher New York Heart Association class, lower systolic blood pressure, higher creatinine, higher amino-terminal proB-type natriuretic peptide (NTproBNP), and lower maximal oxygen consumption. In unadjusted analysis, there was a significant association between elevated galectin-3 levels and hospitalization-free survival (unadjusted hazard ratio, 1.14 per 3-ng/mL increase in galectin-3; P<0.0001). In multivariable modeling, the prognostic impact of galectin-3 was significantly attenuated by the inclusion of other known predictors, and galectin-3 was no longer a significant predictor after the inclusion of NTproBNP.
CONCLUSIONS: Galectin-3 is elevated in ambulatory heart failure patients and is associated with poor functional capacity and other known measures of heart failure severity. In univariate analysis, galectin-3 was significantly predictive of long-term outcomes, but this association did not persist after adjustment for other predictors, especially NTproBNP. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22016505      PMCID: PMC3261343          DOI: 10.1161/CIRCHEARTFAILURE.111.963637

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  13 in total

1.  Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

Authors:  Roland R van Kimmenade; James L Januzzi; Patrick T Ellinor; Umesh C Sharma; Jaap A Bakker; Adrian F Low; Abelardo Martinez; Harry J Crijns; Calum A MacRae; Paul P Menheere; Yigal M Pinto
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

Review 2.  Biomarkers in heart failure.

Authors:  Eugene Braunwald
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

3.  Galectin-3 in heart failure: high levels are associated with all-cause mortality.

Authors:  Thor Ueland; Pål Aukrust; Kaspar Broch; Svend Aakhus; Rita Skårdal; Pieter Muntendam; Lars Gullestad
Journal:  Int J Cardiol       Date:  2011-06-08       Impact factor: 4.164

4.  Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.

Authors:  Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi
Journal:  Eur J Heart Fail       Date:  2010-06-05       Impact factor: 15.534

5.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.

Authors:  Serge Masson; Roberto Latini; Inder S Anand; Tarcisio Vago; Laura Angelici; Simona Barlera; Emil D Missov; Aldo Clerico; Gianni Tognoni; Jay N Cohn
Journal:  Clin Chem       Date:  2006-06-15       Impact factor: 8.327

Review 6.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review.

Authors:  Jenny A Doust; Eva Pietrzak; Annette Dobson; Paul Glasziou
Journal:  BMJ       Date:  2005-03-19

7.  Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.

Authors:  Umesh C Sharma; Saraswati Pokharel; Thomas J van Brakel; Jop H van Berlo; Jack P M Cleutjens; Blanche Schroen; Sabine André; Harry J G M Crijns; Hans-J Gabius; Jos Maessen; Yigal M Pinto
Journal:  Circulation       Date:  2004-11-01       Impact factor: 29.690

8.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

9.  Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.

Authors:  Dirk J A Lok; Peter Van Der Meer; Pieta W Bruggink-André de la Porte; Erik Lipsic; Jan Van Wijngaarden; Hans L Hillege; Dirk J van Veldhuisen
Journal:  Clin Res Cardiol       Date:  2010-02-04       Impact factor: 5.460

10.  Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.

Authors:  G Michael Felker; Vic Hasselblad; Adrian F Hernandez; Christopher M O'Connor
Journal:  Am Heart J       Date:  2009-07-09       Impact factor: 4.749

View more
  68 in total

Review 1.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 2.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

3.  Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study.

Authors:  Lori B Daniels; Paul Clopton; Gail A Laughlin; Alan S Maisel; Elizabeth Barrett-Connor
Journal:  Am Heart J       Date:  2014-02-18       Impact factor: 4.749

Review 4.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

5.  Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study.

Authors:  Abhinav Sharma; Susanna R Stevens; Joseph Lucas; Mona Fiuzat; Kirkwood F Adams; David J Whellan; Mark P Donahue; Dalane W Kitzman; Ileana L Piña; Faiez Zannad; William E Kraus; Christopher M O'Connor; G Michael Felker
Journal:  JACC Heart Fail       Date:  2017-10       Impact factor: 12.035

Review 6.  Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.

Authors:  Francisco Javier Carrasco-Sánchez; María Inmaculada Páez-Rubio
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

7.  Imaging the patient with a new diagnosis of heart failure in the contemporary era.

Authors:  James E Udelson
Journal:  J Nucl Cardiol       Date:  2015-07-08       Impact factor: 5.952

8.  Plasma galectin 3 and heart failure risk in the Physicians' Health Study.

Authors:  Luc Djoussé; Chisa Matsumoto; Andrew Petrone; Natalie L Weir; Michael Y Tsai; J Michael Gaziano
Journal:  Eur J Heart Fail       Date:  2013-12-04       Impact factor: 15.534

Review 9.  The Current and Potential Clinical Relevance of Heart Failure Biomarkers.

Authors:  Parul U Gandhi; Jeffrey M Testani; Tariq Ahmad
Journal:  Curr Heart Fail Rep       Date:  2015-10

10.  Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure.

Authors:  Benjamin French; Le Wang; Bonnie Ky; Jeffrey Brandimarto; Anupam Basuray; James C Fang; Nancy K Sweitzer; Thomas P Cappola
Journal:  J Card Fail       Date:  2015-11-10       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.